These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

320 related articles for article (PubMed ID: 17257090)

  • 1. Memantine in the treatment of mild-to-moderate Alzheimer's disease.
    Cosman KM; Boyle LL; Porsteinsson AP
    Expert Opin Pharmacother; 2007 Feb; 8(2):203-14. PubMed ID: 17257090
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The molecular basis of memantine action in Alzheimer's disease and other neurologic disorders: low-affinity, uncompetitive antagonism.
    Lipton SA
    Curr Alzheimer Res; 2005 Apr; 2(2):155-65. PubMed ID: 15974913
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Alzheimer's disease and the glutamate NMDA receptor.
    Doraiswamy PM
    Psychopharmacol Bull; 2003; 37(2):41-9. PubMed ID: 14566213
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Paradigm shift in NMDA receptor antagonist drug development: molecular mechanism of uncompetitive inhibition by memantine in the treatment of Alzheimer's disease and other neurologic disorders.
    Lipton SA
    J Alzheimers Dis; 2004 Dec; 6(6 Suppl):S61-74. PubMed ID: 15665416
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Memantine: a therapeutic drug for Alzheimer's disease and the comparison with MK-801].
    Kato T
    Nihon Yakurigaku Zasshi; 2004 Sep; 124(3):145-51. PubMed ID: 15333987
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Memantine: from the original brand to generics].
    Titova NV
    Zh Nevrol Psikhiatr Im S S Korsakova; 2017; 117(10):136-143. PubMed ID: 29171502
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and tolerability of memantine in the treatment of dementia.
    Rossom R; Adityanjee ; Dysken M
    Am J Geriatr Pharmacother; 2004 Dec; 2(4):303-12. PubMed ID: 15903287
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Glutamate-related excitotoxicity neuroprotection with memantine, an uncompetitive antagonist of NMDA-glutamate receptor, in Alzheimer's disease and vascular dementia].
    Tanović A; Alfaro V
    Rev Neurol; 2006 May 16-31; 42(10):607-16. PubMed ID: 16703529
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Rationale for combination therapy with galantamine and memantine in Alzheimer's disease.
    Grossberg GT; Edwards KR; Zhao Q
    J Clin Pharmacol; 2006 Jul; 46(7 Suppl 1):17S-26S. PubMed ID: 16809811
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Contemporary issues in the treatment of Alzheimer's disease: tangible benefits of current therapies.
    Tariot PN
    J Clin Psychiatry; 2006; 67 Suppl 3():15-22; quiz 23. PubMed ID: 16649847
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Memantine: targeting glutamate excitotoxicity in Alzheimer's disease and other dementias.
    Molinuevo JL; Lladó A; Rami L
    Am J Alzheimers Dis Other Demen; 2005; 20(2):77-85. PubMed ID: 15844753
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Neuropathologic changes in Alzheimer's disease: potential targets for treatment.
    Wenk GL
    J Clin Psychiatry; 2006; 67 Suppl 3():3-7; quiz 23. PubMed ID: 16649845
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Memantine treatment in patients with mild to moderate Alzheimer's disease: results of a randomised, double-blind, placebo-controlled 6-month study.
    Bakchine S; Loft H
    J Alzheimers Dis; 2007 Jul; 11(4):471-9. PubMed ID: 17656827
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pooled analyses on cognitive effects of memantine in patients with moderate to severe Alzheimer's disease.
    Emre M; Mecocci P; Stender K
    J Alzheimers Dis; 2008 Jun; 14(2):193-9. PubMed ID: 18560130
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The NMDA receptor antagonist memantine as a symptomatological and neuroprotective treatment for Alzheimer's disease: preclinical evidence.
    Danysz W; Parsons CG
    Int J Geriatr Psychiatry; 2003 Sep; 18(Suppl 1):S23-32. PubMed ID: 12973747
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pathologically-activated therapeutics for neuroprotection: mechanism of NMDA receptor block by memantine and S-nitrosylation.
    Lipton SA
    Curr Drug Targets; 2007 May; 8(5):621-32. PubMed ID: 17504105
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The neuropharmacological basis for the use of memantine in the treatment of Alzheimer's disease.
    Rogawski MA; Wenk GL
    CNS Drug Rev; 2003; 9(3):275-308. PubMed ID: 14530799
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Memantine treatment in mild to moderate Alzheimer disease: a 24-week randomized, controlled trial.
    Peskind ER; Potkin SG; Pomara N; Ott BR; Graham SM; Olin JT; McDonald S
    Am J Geriatr Psychiatry; 2006 Aug; 14(8):704-15. PubMed ID: 16861375
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Classics in Chemical Neuroscience: Memantine.
    Alam S; Lingenfelter KS; Bender AM; Lindsley CW
    ACS Chem Neurosci; 2017 Sep; 8(9):1823-1829. PubMed ID: 28737885
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Management of moderate to severe Alzheimer's disease: focus on memantine.
    Dominguez E; Chin TY; Chen CP; Wu TY
    Taiwan J Obstet Gynecol; 2011 Dec; 50(4):415-23. PubMed ID: 22212311
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.